Stock INSM INSMED INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Insmed Incorporated

Equities

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
25.55 USD -0.43% Intraday chart for Insmed Incorporated +3.02% -17.55%
23/04 Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases MT
11/04 Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,134 3,391 3,224 2,707 4,433 3,796 - -
Enterprise Value (EV) 1 2,003 3,231 3,089 2,863 4,993 4,350 4,452 4,476
P/E ratio -7.93 x -11.1 x -7.02 x -5.11 x -5.8 x -5.53 x -6.53 x -10.6 x
Yield - - - - - - - -
Capitalization / Revenue 15.6 x 20.6 x 17.1 x 11 x 14.5 x 10.7 x 7.54 x 4.52 x
EV / Revenue 14.7 x 19.6 x 16.4 x 11.7 x 16.4 x 12.2 x 8.85 x 5.33 x
EV / EBITDA -8.9 x -12.9 x -8.58 x -6.4 x -7.14 x -6.36 x -6.44 x -13.3 x
EV / FCF -6.84 x -14.3 x -8.34 x -6.98 x -9.09 x -6.64 x -7.18 x -14.4 x
FCF Yield -14.6% -6.98% -12% -14.3% -11% -15.1% -13.9% -6.96%
Price to Book 8.18 x 12.4 x 6.82 x 30.8 x -13.1 x -19.3 x -16.7 x 41.5 x
Nbr of stocks (in thousands) 89,344 1,01,868 1,18,372 1,35,477 1,43,062 1,48,555 - -
Reference price 2 23.88 33.29 27.24 19.98 30.99 25.55 25.55 25.55
Announcement Date 25/02/20 25/02/21 17/02/22 23/02/23 22/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 136.5 164.4 188.5 245.4 305.2 356.4 503.1 839.3
EBITDA 1 -225.1 -251.1 -359.8 -447 -699 -683.6 -691.1 -336.2
EBIT 1 -235.2 -265.2 -375.1 -457.3 -709.6 -673.6 -617.6 -369.8
Operating Margin -172.38% -161.32% -199.03% -186.39% -232.51% -189.02% -122.76% -44.06%
Earnings before Tax (EBT) 1 -253.6 -292.7 -436.4 -480.2 -747 -723.3 -687.8 -446.2
Net income 1 -254.3 -294.1 -434.7 -481.5 -749.6 -723.3 -672 -427.7
Net margin -186.37% -178.87% -230.63% -196.26% -245.59% -202.97% -133.57% -50.96%
EPS 2 -3.010 -3.010 -3.880 -3.910 -5.340 -4.616 -3.910 -2.421
Free Cash Flow 1 -292.9 -225.6 -370.6 -410.3 -549.5 -655.4 -620.2 -311.6
FCF margin -214.64% -137.21% -196.64% -167.23% -180.05% -183.9% -123.28% -37.13%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 25/02/20 25/02/21 17/02/22 23/02/23 22/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 46.76 56.12 53.11 65.22 67.73 59.3 65.21 77.23 79.07 83.69 78.53 88.51 92.11 95.73 -
EBITDA 1 -100.1 -95.43 -87.28 -86.1 -125.6 -148 -145.6 -233 -144.9 -175.5 -178 -190 -172 -179 -
EBIT 1 -103.6 -99.08 -89.83 -88.32 -127.7 -151.5 -148.2 -235.5 -147.7 -178.3 -172.6 -168.9 -163.6 -168.4 -
Operating Margin -221.61% -176.53% -169.15% -135.41% -188.54% -255.44% -227.19% -304.97% -186.75% -213.01% -219.8% -190.81% -177.59% -175.89% -
Earnings before Tax (EBT) 1 -115.3 -113 -94.24 -95.14 -130.8 -160 -159.3 -244.3 -158.4 -185.1 -182.8 -180.4 -175.2 -179.5 -
Net income 1 -112.7 -113 -94.62 -95.64 -131.1 -160.1 -159.8 -244.8 -158.9 -186.1 -180.2 -176.7 -169.5 -184.5 -
Net margin -241.06% -201.3% -178.17% -146.65% -193.63% -270.02% -244.98% -316.99% -201% -222.31% -229.48% -199.62% -184.03% -192.7% -
EPS 2 -0.9600 -0.9500 -0.8000 -0.8000 -1.090 -1.210 -1.170 -1.780 -1.110 -1.280 -1.239 -1.136 -1.082 -1.150 -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 28/10/21 17/02/22 05/05/22 04/08/22 27/10/22 23/02/23 04/05/23 03/08/23 26/10/23 22/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 156 560 554 656 681
Net Cash position 1 130 161 135 - - - - -
Leverage (Debt/EBITDA) - - - -0.3486 x -0.8004 x -0.8109 x -0.9491 x -2.025 x
Free Cash Flow 1 -293 -226 -371 -410 -550 -655 -620 -312
ROE (net income / shareholders' equity) -108% -109% -127% -193% - - -609% -44.2%
ROA (Net income/ Total Assets) - - -42.6% -33.2% -50.2% -60.2% -69.8% -
Assets 1 - - 1,020 1,450 1,493 1,202 962.8 -
Book Value Per Share 2 2.920 2.680 3.990 0.6500 -2.360 -1.320 -1.530 0.6200
Cash Flow per Share 2 - -2.250 -3.240 -3.250 -3.820 -3.610 -2.870 -
Capex 1 42.3 6.24 7.29 9.88 13.3 12.6 13.3 14
Capex / Sales 30.97% 3.8% 3.87% 4.03% 4.35% 3.54% 2.65% 1.67%
Announcement Date 25/02/20 25/02/21 17/02/22 23/02/23 22/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Insmed Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
25.55 USD
Average target price
44.12 USD
Spread / Average Target
+72.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
INSMED INCORPORATED Stock Insmed Incorporated
-17.55% 3.8B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. INSM Stock
  4. Financials Insmed Incorporated